UBS Group’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

UBS Group’s Portfolio DMAAU Stock Details DMAAU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.2K	Buy	1,525 +4	+0.3%	+$43	﹤0.01%	8286
2026 Q1	$16K	Sell	1,521 -6,500	-81%	-$68.4K	﹤0.01%	8091
2025 Q4	$84.3K	Sell	8,021 -10,364	-56%	-$109K	﹤0.01%	6994
2025 Q3	$191K	Hold	18,385	–	–	﹤0.01%	6702
2025 Q2	$190K	Buy	18,385 +107	+0.6%	+$1.09K	﹤0.01%	6761
2025 Q1	$186K	Buy	+18,278	New	+$184K	﹤0.01%	6603

Other funds holding DMAAU

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group's DMAAU Position: Q2 2026 in Review

UBS Group increased its Drugs Made In America Acquisition Corp Units (DMAAU) stake by 0.26% in Q2 2026, buying an estimated $43 and bringing the position to 1,525 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #8286.

UBS Group first reported a position in DMAAU in Q1 2025 and has held it in 6 quarters since. The position peaked at $191K in Q3 2025. 2 funds tracked by Wall St. Rank hold DMAAU as of Q2 2026.

UBS Group held 1,525 shares of Drugs Made In America Acquisition Corp Units worth $16.2K as of Q2 2026.
UBS Group bought 4 Drugs Made In America Acquisition Corp Units shares in Q2 2026, an estimated $43.
Drugs Made In America Acquisition Corp Units made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8286 holding.
UBS Group first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and has held it in 6 quarters since.
UBS Group's Drugs Made In America Acquisition Corp Units position peaked at $191K in Q3 2025.
2 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.